Roche has announced plans to jointly develop an early-stage monoclonal antibody against cancer with Genentech Inc and its wholly-owned Swiss unit, GlycArt Biotechnology AG. The molecule was discovered by GlycArt, a spin-out of the Swiss Federal Institute of Technology in Zurich. GlycArt was acquired by Roche in July 2005.
